HC Wainwright Analysts Lower Earnings Estimates for TRDA
HC Wainwright analysts have reduced their Q3 2026 earnings per share estimates for Entrada Therapeutics (NASDAQ:TRDA) to a loss of $1.18, maintaining a "Neutral" rating. The company's recent quarterly results missed expectations, reporting a $1.01 loss per share against an anticipated $0.97 loss, and …